Marketing-Börse PLUS - Fachbeiträge zu Marketing und Digitalisierung
print logo

Increased Awareness will Aid in Market Growth of Cell-Free DNA (cfDNA) Testing During 2017 - 2025

The cell-free fetal DNA market has a major share in the market due to increased number of pregnancies following to it is the circulating cell-free tum
MarketsandMarkets™ | 26.02.2018

 

Cell-Free DNA are fragments of DNA which circulate in the blood fluid and can be utilized as valuable biomarkers. It is a new technology in which small quantity of liquid sample (saliva, urine, or blood) from the patient is collected to examine the freely flowing DNA. Cell-Free DNA (cfDNA) is a noninvasive screening test used to help detect graft rejection, identify mutations in cancer patients and detect various chromosomal abnormalities in the fetus, to know the gender of the fetus. The discovery of cfDNA has opened up to new potentials in the field of oncology, gynecology, transplantation and infectious diseases. 

Request for Table of Contents @ https://www.persistencemarketresearch.com/toc/16249 

Cell-Free DNA are fragments of DNA which circulate in the blood fluid and can be utilized as valuable biomarkers. It is a new technology in which small quantity of liquid sample (saliva, urine, or blood) from the patient is collected to examine the freely flowing DNA. Cell-Free DNA (cfDNA) is a noninvasive screening test used to help detect graft rejection, identify mutations in cancer patients and detect various chromosomal abnormalities in the fetus, to know the gender of the fetus. The discovery of cfDNA has opened up to new potentials in the field of oncology, gynecology, transplantation and infectious diseases. 

The cell-free fetal DNA market has a major share in the market due to increased number of pregnancies following to it is the circulating cell-free tumor DNA market, and later the donor-derived cell-free DNA market. In the region wise segmentation, North America region had the largest revenue in 2015 due to the majority of tests launched and adaptation of advanced technologies in screening techniques. Following North America is Europe and Asia Pacific which are also the fastest growing market due to growing economy and improving healthcare infrastructure and rising prevalence of diseases in these regions. The potential of cell-free DNA testing market has attracted many biotechnology and pharmaceutical firms by acquiring other major firms or by launching novel tests. 

Get Sample Copy of this Report @ https://www.persistencemarketresearch.com/samples/16249 

The cell-free fetal DNA market has a major share in the market due to increased number of pregnancies following to it is the circulating cell-free tumor DNA market, and later the donor-derived cell-free DNA market. In the region wise segmentation, North America region had the largest revenue in 2015 due to the majority of tests launched and adaptation of advanced technologies in screening techniques. Following North America is Europe and Asia Pacific which are also the fastest growing market due to growing economy and improving healthcare infrastructure and rising prevalence of diseases in these regions. The potential of cell-free DNA testing market has attracted many biotechnology and pharmaceutical firms by acquiring other major firms or by launching novel tests. 

Various companies are coming up with new software and improved sequencing technologies which have improved the test quality with accurate and rapid results. Some of the leading players in cell-free DNA testing market are Agilent Technology, Allenex AB, Biocept, Inc., Biodesix, Inc., CareDx, Inc. Guardant Health, Inc., Illumania, Inc., Invited Limited, Natera, Inc., Quest Diagnostics, Roche Holdings AG, Sequenom, Inc. and Trovagene, Inc. The global cell-free DNA testing market is a competitive market, and all the players are involved in developing new assays by mergers and acquisitions to sustain themselves in the market and maintain their market share. For instance, Roche Holdings AG received U.S. FDA approval for its newly launched ctDNA test Cobas which is approved for blood-based genetic tests. Roche also entered the NIPT market with the acquisition of Ariosa Diagnostics. CareDx, Inc., acquired Allenex AB for its new developments in donor-derived Cell-Free DNA tests for kidney and heart transplant patients.

Report Overview @ https://www.persistencemarketresearch.com/market-research/cell-free-dna-cfdna-testing-market.asp 

About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us

Persistence Market Research

305 Broadway

7th Floor, New York City,

NY 10007, United States,

Telephone - +1-646-568-7751

USA – Canada Toll Free: 800-961-0353

Email: sales@persistencemarketresearch.com

Web: http://www.persistencemarketresearch.com

 

 

Img of MarketsandMarkets™
About the tenderer: MarketsandMarkets™

MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports.